IMPower010: Overall survival interim analysis of a Phase III study of atezolizumab vs best supportive care in resected NSCLC
(Vienna, August 8, 2022, 10:30 a.m. CEST)--An interim analysis of overall survival data from the IMpower010 trial showed an overall ...